Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976183 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
A Phase 1 study, sponsored by Gynecologic Oncology Associates.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00976183 is a Phase 1 study that was terminated before completion, run by Gynecologic Oncology Associates. The registered enrollment target is 18 participants.
The verdict
NCT00976183, a Phase 1 study, was terminated before completion, sponsored by Gynecologic Oncology Associates.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow \& Curtin, 1998). Currently, no triplet regimen has demonstrated compelling superiority. Therefore, the combination of Paclitaxel, Carboplatin, and Vorinostat is intriguing because of their potential synergy, distinct mechanisms of action, and non-overlapping toxicity.
Interventions
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976183
The ClinicalTrials.gov registry entry for NCT00976183 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Associates, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vorinostat is the first listed.
NCT00976183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976183 about?
NCT00976183 is a clinical study titled "Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma". Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow \& Curtin, 1998). Currently, no triplet regimen has demonstrated compelling superiority. Therefore, the combi...
What is the current status of trial NCT00976183?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-10. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00976183?
The interventions under investigation include: Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00976183?
This trial is sponsored by Gynecologic Oncology Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.